PDF document

Azulfidine - Pfizer

Severe, life-threatening, systemic hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking sulfasalazine. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.

Source: labeling.pfizer.com

Open / Download at source Report this link

Related files to “azulfidine-pfizer”

PDF

SUMMARY OF PRODUCT CHARACTERISTICS - Medac

The possibly life-threatening agranulocytosis expresses itself in a general feeling of illness, associated with fever, chills, palpitations, sore throat and difficulty swallowing as well as painful inflammation of the mucous membranes in the mouth, nose and throat area as well as in the anal and genital area. In these cases, sulfasalazine must be discontinued immediately. Sulfasalazine should ...

PDF

SULPHASALAZINE TABLETS 500 MG - Summary of medicine characteristics

For sulfasalazine given as a single 3g oral dose, peak serum levels of sulfasalazine occurred in 3–5 hours, elimination half-life was 5.7 ±0.7 hours, lag time 1.5 hours.

PDF

label - Food and Drug Administration

The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. In fast acetylators, the mean plasma half-life of SP is 10.4 hours while in slow acetylators, it is 14.8 hours.

PDF

Sulfasalazine Tablets

Severe, life-threatening, systemic hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms DRESS have been reported in patients taking sulfasalazine. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.

PDF